Abstract
The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Current Neurovascular Research
Title: Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Volume: 8 Issue: 3
Author(s): Andrei Anghel, Georgel Taranu, Edward Seclaman, Andreea Rata, Liviu Tamas, Horatiu Moldovan, Sorin Ursoniu, Corina Samoila, Mihai Ionac and Aurel Popa-Wagner
Affiliation:
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Abstract: The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Export Options
About this article
Cite this article as:
Anghel Andrei, Taranu Georgel, Seclaman Edward, Rata Andreea, Tamas Liviu, Moldovan Horatiu, Ursoniu Sorin, Samoila Corina, Ionac Mihai and Popa-Wagner Aurel, Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia, Current Neurovascular Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720211796558050
DOI https://dx.doi.org/10.2174/156720211796558050 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders
Current Aging Science MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Current Pharmaceutical Design Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Role of Infrasound Pressure Waves in Atherosclerotic Plaque Rupture: A theoretical Approach
Recent Patents on Cardiovascular Drug Discovery Perioperative Management of Patients on Adenosine Diphosphate Inhibitors in the Era of Drug-Eluting Stents: Review of the Literature and Clinical Implications
Current Medicinal Chemistry Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Current Topics in Medicinal Chemistry Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Neuronal Nitric Oxide Synthase and Sympathetic Nerve Activity in Neurovascular and Metabolic Systems
Current Neurovascular Research Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk
Current Pharmaceutical Design Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Nifedipine Inhibits the Progression of An Experimentally Induced Cerebral Aneurysm in Rats with Associated Down-Regulation of NF-Kappa B Transcriptional Activity
Current Neurovascular Research Recent Advances in Exercise Testing
Current Cardiology Reviews